Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment

J Immunol Res. 2022 Mar 18:2022:8052212. doi: 10.1155/2022/8052212. eCollection 2022.

Abstract

With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines* / therapeutic use
  • Humans
  • Immunologic Factors
  • Immunotherapy / methods
  • Immunotherapy, Adoptive
  • Neoplasms*

Substances

  • Cancer Vaccines
  • Immunologic Factors